Literature DB >> 28320298

Sodium Orthovanadate Inhibits Proliferation and Triggers Apoptosis in Oral Squamous Cell Carcinoma in vitro.

A A Khalil1, M J Jameson.   

Abstract

Sodium orthovanadate (SOV) is a general inhibitor of tyrosine phosphatases, a large family of enzymes that catalyze the removal of phosphate groups from tyrosine residues. SOV is commonly used in the laboratory to preserve the protein tyrosyl phosphorylation state of proteins under study. It has shown promising antineoplastic activity in some human cancer cell lines; this effect has not been fully investigated in head and neck squamous cell carcinoma. In this study, the effect of SOV on cell growth, proliferation, viability, and apoptosis was assessed in Cal27 cells, an oral squamous cell carcinoma (OSCC) cell line. SOV exhibited dose-dependent inhibition of cell growth and decrease in cell viability and colony formation. The IC50 values for treatment lasting 72 h and 7 days were 25 and 10 µM, respectively. The cytotoxic effect of the drug was associated with poly(ADP-ribose)polymerase cleavage detected by immunoblot. Flow cytometry of Cal27 cells stained with annexin V-FITC and propidium iodide showed a dose-dependent increase in apoptosis that reached approximately 40% at 25 µM SOV. These findings demonstrate that SOV has in vitro antiproliferative and proapoptotic effect on OSCC cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28320298     DOI: 10.1134/S0006297917020067

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  7 in total

1.  Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro.

Authors:  Ashraf Khalil; Mark J Jameson
Journal:  Horm Cancer       Date:  2018-10-23       Impact factor: 3.869

2.  The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.

Authors:  Ashraf Khalil; Mark J Jameson
Journal:  Drugs R D       Date:  2017-12

3.  Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways.

Authors:  Wenjing Jiang; Guangxin Li; Weidong Li; Ping Wang; Peng Xiu; Xian Jiang; Bing Liu; Xueying Sun; Hongchi Jiang
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

4.  Sodium Orthovanadate Changes Fatty Acid Composition and Increased Expression of Stearoyl-Coenzyme A Desaturase in THP-1 Macrophages.

Authors:  Jan Korbecki; Izabela Gutowska; Marta Wiercioch; Agnieszka Łukomska; Maciej Tarnowski; Arleta Drozd; Katarzyna Barczak; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Biol Trace Elem Res       Date:  2019-03-29       Impact factor: 3.738

5.  Anticancer effect of sodium metavanadate on murine breast cancer both in vitro and in vivo.

Authors:  Yu Tian; Haihui Qi; Gang Wang; Li Li; Dinglun Zhou
Journal:  Biometals       Date:  2021-03-10       Impact factor: 2.949

Review 6.  Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells.

Authors:  Szymon Kowalski; Dariusz Wyrzykowski; Iwona Inkielewicz-Stępniak
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

7.  Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent.

Authors:  Hien Thi Thu Le; Tatu Rimpilainen; Saravanan Konda Mani; Akshaya Murugesan; Olli Yli-Harja; Nuno R Candeias; Meenakshisundaram Kandhavelu
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.